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Human monogenic pain syndromes have provided
important insights into the molecular mechanisms
that underlie normal and pathological pain states.
We describe an autosomal-dominant familial
episodic pain syndrome characterized by episodes
of debilitating upper body pain, triggered by fasting
and physical stress. Linkage and haplotype analysis
mapped this phenotype to a 25 cM region on chro-
mosome 8q12–8q13. Candidate gene sequencing
identified a point mutation (N855S) in the S4 trans-
membrane segment of TRPA1, a key sensor for envi-
ronmental irritants. The mutant channel showed
a normal pharmacological profile but altered
biophysical properties, with a 5-fold increase in
inward current on activation at normal resting poten-
tials. Quantitative sensory testing demonstrated
normal baseline sensory thresholds but an enhanced
secondary hyperalgesia to punctate stimuli on treat-
ment with mustard oil. TRPA1 antagonists inhibit the
mutant channel, promising a useful therapy for this
disorder. Our findings provide evidence that varia-
tion in the TRPA1 gene can alter pain perception in
humans.
INTRODUCTION
Inherited human neurological disorders caused by mutations in
ion channels encompass a diverse range of conditions including
pathological pain states (Indo, 2001; Yang et al., 2004;
Einarsdottir et al., 2004; Cox et al., 2006; Fertleman et al.,Neuron 66, 671–680,2006; Foulkes and Wood, 2008). Voltage-gated Na+ and Ca2+
channelopathies account for many cases of familial hemiplegic
migraine and epilepsy, while K+ channel mutations have been
associated with epilepsy, peripheral nerve hyperexcitability,
and ataxia (Kullmann and Hanna, 2002). Dominant gain-of-func-
tion mutations of the peripheral nervous system sodium channel
NaV1.7 have been linked to the painful disorders paroxysmal
extreme pain disorder and erythermalgia (Yang et al., 2004; Fer-
tleman et al., 2006; Dib-Hajj et al., 2007). Loss of functional
NaV1.7 channel activity leads to congenital insensitivity to pain
(Cox et al., 2006).
Transient receptor potential (TRP) channels are cation chan-
nels that are implicated in all aspects of sensation, including
vision, olfaction, mechanosensation, thermosensation, and
damage sensing (Nilius, 2007). However, no human heritable
disorders of pain sensation have as yet been linked to mutations
in TRP channels, despite knockout mouse studies that suggest
a number of TRPs play an important role in pain pathways (Cregg
et al., 2010). Mutations in TRPV4 (which is activated by innoc-
uous heat and hypotonicity and is a putative mechanosensor)
do not alter pain responses, but underlie two different neurode-
generative diseases, scapuloperoneal spinal muscular atrophy
and Charcot-Marie-Tooth disease type 2C (Auer-Grumbach
et al., 2010; Deng et al., 2010; Landoure et al., 2010) as well as
two forms of skeletal dysplasia (Rock et al., 2008; Krakow
et al., 2009). TRPA1 is expressed in primary afferent nociceptors
in rodents and man (Story et al., 2003; Anand et al., 2008) and
has been shown to play an important role in the response to envi-
ronmental irritants in mouse models (Kwan et al., 2006; Bautista
et al., 2006; McMahon and Wood, 2006). There is also strong
evidence that TRPA1 is gated by cold temperatures and debate
about whether the channel is mechanosensitive (Kwan et al.,
2006; Rugiero and Wood, 2009). Here we describe the identifica-
tion of a point mutation in the S4 domain of TRPA1 that underlies
an autosomal dominant Mendelian heritable episodic painJune 10, 2010 ª2010 Elsevier Inc. 671Open access under CC BY license.
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Episodes are triggered by conditions of fatigue, fasting, and cold
and result in severe pain localized principally to the upper body.
By comparing the biophysical properties of the expressed mutant
channel with wild-type (WT) TRPA1, we have been able to identify
a mechanism that is likely to underlie the painful episodes. To our
knowledge, this is the first example of a human pain-associated
TRP channelopathy and is likely to be followed by further genetic
insights into the role of TRP channels in pain pathways as pain-
related genome-wide association studies come to fruition.
RESULTS
Mapping the Familial Episodic Pain Syndrome Mutation
Individuals with FEPS present with episodes of debilitating upper
body pain starting in infancy that are usually triggered by fasting
or fatigue (illness, cold temperature, and physical exertion being
contributory factors). Triggers did not start attacks with 100%
reliability and often a combination of factors are needed; a typical
example would be swimming in cold water not having eaten for
a number of hours. These episodes have a typical duration of
1.5 hr, starting with a prodromal phase (which can sometimes
be aborted, mainly by resting and eating), followed by intense
pain, and terminating in a period of exhaustion and deep sleep.
The period of intense pain is accompanied by breathing diffi-
culties, tachycardia, sweating, generalized pallor, peribuccal
cyanosis, and stiffness of the abdominal wall. Affected individ-
uals reported no altered pain sensitivity outside the episodes.
They had a normal neurological examination, including normal
sensitivity to light touch, pin prick, vibration sense, and joint posi-
tion sense. Other than the Colombian pedigree described here
we are not aware of any previous reports of this clinical
syndrome (see Supplemental Information for illustrative case
history and Tables S1–S4 summarizing clinical features, avail-
able online). A total of 21 affected family members in four gener-
ations were identified by pedigree extension, consistent with an
autosomal dominant mode of inheritance (individuals included in
the study are shown in Figure 1A).
We performed a genome-wide linkage scan with 550 micro-
satellite markers in 13 affected and 10 unaffected family
members (Figure 1A). Parametric linkage analysis produced
positive LOD scores across chromosome 8q12.1–8q24.1, with
a maximum two-point LOD score of 4.18 for marker D8S512
(at q = 0) and a multipoint LOD score of 4.42 between markers
D8S512 and D8S279 (at 8q12.3–8q13.3). Typing of additional
microsatellite markers in the region resulted in a maximum multi-
point LOD score of 5.36 at position 79 cM on chromosome 8q13
and haplotype analysis further narrowed down the candidate
region to an interval of 25 cM spanning chromosome 8q13.2–
8q22.2 (Figure 1). Candidate gene sequencing in affected indi-
viduals identified an A to G transition in exon 22, at position
2564 of the TRP channel member TRPA1 cDNA (c.A2564G;
Figure 2A). This change was observed in all affected individuals
but not in unaffected family members. Sequencing of 139 ethni-
cally matched unaffected controls failed to detect the c.A2564G
mutation in the general population. This mutation results in the
substitution of an asparagine by a serine (N855S) in the putative
transmembrane segment S4 of TRPA1 (Figure 2B). TRPA1,672 Neuron 66, 671–680, June 10, 2010 ª2010 Elsevier Inc.which contains N-terminal ankyrin repeats, is a homolog of the
NOMPC channel involved in hearing in Drosophila. However,
knockout mouse studies have demonstrated an important role
for TRPA1 in response to irritant chemicals, but not hearing
(Kwan et al., 2006; Bautista et al., 2006). Zebrafish TRPA1 is
also mechanically insensitive (Prober et al., 2008).
Psychophysical Studies of FEPS Patients
Skin biopsies were obtained from three subjects with the N855S
TRPA1 mutation and three unaffected relatives. Both the
morphology and density of intraepidermal nerve fibers (revealed
by immunostaining with the pan-neuronal marker PGP 9.5) were
normal (Figure S1). Quantitative sensory testing (QST) was per-
formed in nine individuals with FEPS and in eight unaffected rela-
tives. No significant difference was observed in tactile detection
threshold, vibration detection threshold, or cold, heat, or pres-
sure pain detection threshold in mutation carriers (Table S4).
Mustard oil (Allyl isothiocyanate) is known to activate TRPA1
and in humans it has been shown to produce ongoing pain,
a cutaneous flare response, and sensitization of the nociceptive
system (Koltzenburg et al., 1992; Jordt et al., 2004). No signifi-
cant difference was observed in the pain response [as assessed
by visual analog scale (VAS)] during application of 50% mustard
oil when comparing mutation carriers and non-carriers
(Figure 3B). There was a (non-significant) increase in the mean
flare area comparing FEPS patients versus control (SD in paren-
theses): 7.2 cm2 (±4.6) and 3.9 (±2.4), respectively (p = 0.1
unpaired t test; Figure 3C). Some (4/8) FEPS patients developed
very large flares (of over 8 cm2) at 10 min after mustard oil appli-
cation, whereas this reaction was not seen in the controls. Muta-
tion carriers also showed a significant increase in the area of
punctate hyperalgesia at 10 and 60 min after mustard oil applica-
tion (p < 0.05, unpaired t test; Figure 3D) and a (non-significant)
increase in the area of brush-evoked allodynia (Figure 3E). We
were not able to perform extensive dose-response studies using
mustard oil, however, as an initial trial (to assess tolerability) of
0.5% mustard oil was applied to the volar forearm and this did
not evoke a response in either FEPS patients or control.
Biophysical Studies of the FEPS-Associated TRPA1
Mutant Channel
Clones encoding the WT and N855S mutant human TRPA1
channel were expressed in HEK293 cells and characterized elec-
trophysiologically using the whole cell patch configuration (Story
et al., 2003). Calcium imaging studies used FURA-2-loaded
HEK293 cells and OpenLab software as described previously
(Abrahamsen et al., 2008). The half maximum effective concen-
tration (EC50) for cinnamaldehyde (CA), a ligand that covalently
modifies and activates TRPA1, was similar in both WT and
mutant channels and in the range of the reported value for
TRPA1—61 mM (Bandell et al., 2004) (Figures 4A and 4B). This
is consistent with the mutation being distant from the N-terminal
region, which has been implicated in CA binding (Hinman et al.,
2006; Macpherson et al., 2007). However, the current-voltage
relationship of the mutant channel revealed by ramp protocols
was dramatically altered by the N855S mutation. Current-
voltage plots in transfected cells in the absence of agonist
were identical with both WT and mutant channels (Figure S2A).
Figure 1. Genetic Mapping of the Mutant
Locus Underlying FEPS
(A) Pedigree segregating FEPS. Microsatellite
haplotypes spanning the linkage peak on chromo-
some 8q12.1–8q24.1 identified in the whole-
genome scan. The haplotypes shown were recon-
structed using markers from the whole-genome
scan and fine-mapping stages. The haplotype co-
segregating with the pain phenotype is shown in
red. The minimal critical region spans 25 cM and
is flanked by marker D8S1775 on the centromeric
end and marker D8S1762 on the telomeric end
(informative recombinants individuals being III:8
and II:5, respectively). Only individuals included
in the linkage analysis are shown (individuals
with an asterisk were unavailable for genotyping).
(B) Multipoint LOD scores obtained on chromo-
some 8 (including fine-mapping markers) and
location of the TRPA1 gene. Physical distance
(in Mb) is shown at the top and genetic distance
(in cM) at the bottom. The dotted lines indicate
the LOD score thresholds of 3 and 2 (i.e., signif-
icant evidence for or against linkage, respectively).
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potentials (60 to 70 mV) showed that the mutant channel
carried considerably more current than the outwardly rectifying
WT channel (Figures 4C and 4D). While outward currents were
identical at +100 mV in WT and mutant channels, at 100 mVNeuron 66, 671–6the mutant channel carried 5.4-fold
more current (Figure 4C, WT: 100 mV =
0.13 ± 0.02, +100 mV = 0.93 ± 0.04;
mutant: 100 mV = 0.68 ± 0.04, +100
mV = 0.95 ± 0.03). At normal neuronal
resting potentials, >4-fold increase in
current was observed (Figure 4D, WT:
70 mV = 0.12 ± 0.02; mutant: 70
mV = 0.48 ± 0.02). Furthermore, no dif-
ference in current density was recorded
between WT and mutant channel [current
density (pA/pF) for WT at +100 mV =
0.09 ± 0.02 and mutant at +100 mV =
0.08 ± 0.02], thus ruling out possible
effects on trafficking of the channel. Both
WT and mutant channels were blocked by
the non-selective calcium channel blocker
ruthenium red (Figures 4A and 4C). The
increase in inward current was accompa-
nied by a leftward shift in the midpoint
(V1/2) of voltage activation curves derived
from tail currents from +58.0 ± 2.1 mV
in the WT channel to +1.7 ± 2.1 mV in
the mutant channel (Figures 4E–4G). No
change in voltage sensitivity was ob-
served between WT and mutant channels
(k = 52.3 ± 1.25 mV and 49.3 ± 1.56 mV
for WT and mutant, respectively). Never-
theless, the small shift of the activationcurves at negative potentials alone cannot account for the large
increase in current in the mutant channel. This suggests that
N855S mutation is also likely to affect the gating of TRPA1. In
nominally Ca2+-free external solution, the TRPA1 half-activation
voltages for WT and mutant channel were +83.3 ± 1.1 mV80, June 10, 2010 ª2010 Elsevier Inc. 673
Figure 2. Identification of a Point Mutation Underlying FEPS
(A) Sequence chromatogram showing the TRPA1 mutation identified in the
FEPS family. The arrow indicates the location of the mutation. Below is a selec-
tion of mammalian TRPA1 sequences showing that the mutation site region is
evolutionarily conserved.
(B) Schematic representation of the TRPA1 channel. The substitution (S) iden-
tified in the FEPS family occurs in asparagine (N) 855 located in putative trans-
membrane segment S4.
Neuron
A Gain-of-Function Mutation in Human TRPA1and +22.8 ± 1.0 mV, respectively (Figure S3). This shift in V1/2
between the WT and mutant channel was the same as in the
presence of Ca2+ (60 mV), suggesting that external Ca2+ has
no role in the shift of activation curves between WT and mutant
channels. Nevertheless, in the absence of Ca2+ the slope of
the voltage-activation curve of the mutant channel was shallower
than the WT [k = 24.3 ± 1.8 mV and 42.2 ± 1.4 mV for WT and
mutant, respectively (p < 0.01); Figure S3]. This demonstrates
that the gating of the mutant channel is closely dependent on
external Ca2+. It is worth noting that current traces at positive
potentials always appear slower in the WT channel when
compared to the mutant channel. This is similar to what is
observed with heat-sensitized TRPV3 channels (Chung et al.,
2005) and constitutes another argument in favor of a change in
voltage dependence and gating of the channel by the N855S674 Neuron 66, 671–680, June 10, 2010 ª2010 Elsevier Inc.mutation. However, whether this has any physiological relevance
is unlikely.
The enhanced activity in the mutant channel was also
apparent when the ligand used was the endogenous mediator
4-hydroxynonenal (4-HNE; Figures 5A and 5B), as well as
mustard oil (Allyl isothiocyanate; Figure S2B) or menthol (Fig-
ure S4). Both WT and mutant channel types were blocked by
the selective antagonist HC-030031 (Figures 5A and 5B).
The mechanism of activation of TRPA1 by cold is a contentious
subject. Here we show that cooling activated both WT and
mutant channels with increased inward currents associated
with the N855S variant (Figure 5C). This is due to a leftward shift
of the activation curve with the mutant channel showing a greater
shift compared to the WT channel (V1/2 = +90.9 ± 1.3 mV and
+62.7 ± 1.6 mV at 25C and 12C, respectively, for WT and
V1/2 = +90.3 ± 1.1 mV and +4.0 ± 1.8 mV at 25C and 12C,
respectively, for the mutant channel; Figure 5D). This effect
was reversed upon application of the TRPA1-specific antagonist
HC-030031 (Figure S5). This shift in voltage dependence of
channel activation toward more negative potentials is similar to
what has been described for other temperature-sensitive TRP
channels (Voets et al., 2004). The increase in inward current in
the mutant channel is therefore independent of activation mech-
anism and is observed with all ligands tested as well as with cold
activation (Table S5).
DISCUSSION
The present study unambiguously identifies a gain-of-function
point mutation in TRPA1 (N855S) as the cause of the previously
undescribed human pain syndrome, which we have named
FEPS. This mutation is highly penetrant, giving rise to stereo-
typed episodes of severe pain affecting principally the upper
body triggered by cold and fasting; there is complete segrega-
tion of the mutation with the clinical syndrome. Biophysical
studies using heterologously expressed channels show that
the N855S mutation does not alter exogenous or endogenous
ligand binding, but does increase current flow through the acti-
vated channel at negative membrane potentials.
FEPS is likely to be rare as it has not previously been described
in the pain literature. A number of conditions such as Fabry’s
disease (Zarate and Hopkin, 2008) or familial amyloid neuropathy
(Wang et al., 2008), which result in injury to nociceptor axons
(small fiber neuropathies), are associated with neuropathic pain
in the extremities. In FEPS patients, however, the pain has a
proximal distribution, is episodic, and intraepidermal nerve fiber
density [a sensitive measure of small fiber neuropathy (Lauria
et al., 2005)] was normal. Therefore, in a manner analogous to
gain-of-function mutations in NaV1.7 (Yang et al., 2004; Fertle-
man et al., 2006; Drenth and Waxman, 2007), FEPS occurs as
a consequence of altered functional properties of nociceptive
afferents. In these patients we did not observe any changes in
baseline mechanical or thermal pain thresholds. However, there
was evidence of enhanced sensitization of the nociceptive
system following application of mustard oil (a TRPA1 agonist).
The greater flare response reflects increased neurogenic inflam-
mation and the increase in the area of punctate hyperalgesia
probably represents enhanced central sensitization due to
Figure 3. Increased Area of Punctate Hyperalgesia in Patients with FEPS after Topical Mustard Oil Application
(A) The area of flare, secondary hyperalgesia to punctate stimuli, and brush-evoked allodynia 10 min after mustard oil application in a patient with FEPS and
a family control.
(B–E) Comparison of pain assessed by VAS during topical mustard oil application (B) and the area of flare (C), punctate hyperalgesia (D), and brush-evoked al-
lodynia (E) at 10, 30, and 60 min after application in FEPS patients versus family controls. All assessments were performed in the same nine cases and eight family
controls, except in (C) where only eight cases where examined. The boxes span the 25th to 75th percentile with the median represented as a solid line and the
mean as a dotted line, the whiskers show the full range of the data. *p < 0.05, unpaired t test.
Neuron
A Gain-of-Function Mutation in Human TRPA1increased nociceptor drive. The initial trigger for TRPA1 activa-
tion is unknown, but the contribution of tiredness, cold, and fast-
ing to the attacks, coupled with the preventive role of food and
warming, suggests that some metabolic dysfunction, for
example, lowered membrane potentials or increased intracel-
lular calcium levels, could contribute to the start of attacks
(Zhang and Lipton, 1999; Velasco et al., 2006).
The molecular basis of FEPS resides in the N855S mutation
present adjacent to a cysteine residue in the putative S4 domain
of TRPA1. Activation of TRPA1 by electrophilic compounds, such
as 4-HNE and mustard oil, has been shown to occur through
covalent modification of N-terminal cysteines (Macpherson
et al., 2007; Peterlin et al., 2007; Trevisani et al., 2007; Materazzi
et al., 2008; Taylor-Clark et al., 2009). In contrast, TRPA1 activa-
tion by non-electrophilic compounds such as menthol is deter-
mined through transmembrane domain 5 (Xiao et al., 2008). The
present studies suggest that agonist binding to the mutant
channel remains unaffected. However, the N855S mutant hascomplex effects on channel behavior, mixing a shift of TRPA1
activation toward more negative voltages and a change in the
gating of TRPA1 through a Ca2+-dependent mechanism.
Previous studies have shown that the voltage dependence of
thermoTRPs is linked to the S4 segment (Voets et al., 2004,
2007). The present results demonstrate that the S4 transmem-
brane segment of TRPA1 contributes to agonist- and tempera-
ture-dependent channel activity. A similar mutation in the S4
segment of TRPM8 at an adjacent amino acid residue (856) also
resulted in a leftward shift in the voltage activation curve (Voets
et al., 2007). This suggests that temperature and ligand regulation
of voltage dependency among thermoTRPs may be conserved.
Our data also suggest that the S4 segment of TRPA1 is
involved in gating the channel via a Ca2+-dependent mechanism.
Internal Ca2+-dependent activation of TRPA1 was shown to
occur through an EF-hand domain in the N terminus of the
channel (Zurborg et al., 2007). Here we show that external
Ca2+ regulates the voltage sensitivity of TRPA1 through the S4Neuron 66, 671–680, June 10, 2010 ª2010 Elsevier Inc. 675
Figure 4. Pharmacological and Biophysical Analysis of hTRPA1-WT and hTRPA1-N855S
(A) Intracellular calcium response to 250 mM, 100 mM, 50 mM, and 10 mM CA and to 100 mM CA in the presence of 3 mM ruthenium red (RR). Results for HEK293
cells expressing hTRPA1-WT are shown on the left and for hTRPA1-N855S on the right. Horizontal bars at the top indicate the time of CA application.
(B) Dose-response curve of CA-evoked calcium responses for hTRPA1-WT and hTRPA1-N855S. [Ca2+]I normalized to maximum calcium response to 250 mM CA.
Traces represent average [Ca2+]I from 20–30 cells. Data were fit to the Hill equation.
(C) HEK293 cells expressing hTRPA1-WT (left; n = 5) or hTRPA1-N855S (right; n = 6) show activation by CA (100 mM) and inhibition by ruthenium red (RR). Currents
were recorded at +100 mV and –100 mV and are normalized to current at +100 mV. Letters denote time point at which voltage ramps (shown in D) were acquired to
generate current-voltage relationships.
(D) Average current-voltage relationship of hTRPA1-WT and hTRPA1-N855S in the presence of 100 mM CA. Currents are normalized to +100 mV.
(E) Whole-cell current traces of HEK293 cells expressing hTRPA1-WT in response to the indicated voltage step protocol in the absence (left) and presence (right)
of 100 mM CA. Bottom panel shows higher resolution of normalized tail current in response to a step to140, 0, and +140 mV. Dotted line shows zero current level.
(F) Same as (E) but in HEK293 cells expressing hTRPA1-N855S.
(G) Mean steady-state activation curves obtained from tail currents (IT) at 140 mV for hTRPA1-WT (n = 5) and hTRPA1-N855S (n = 6) in the presence of CA. The
midpoints of voltage activation (V1/2) for the WT and mutant channels are indicated at the top. Error bars in all plots represent SEM across individual cell measure-
ments.
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of Ca2+ mediated by the S4 segment of a TRP channel. A fasci-
nating aspect of TRPA1 activation lies in interspecies discrep-
ancies.Someelectrophilic thioaminal-containingcompoundsare
able to activate rat TRPA1 while others inhibit human TRPA1
(Chen et al., 2008). This difference is due to key amino acids sit-
uated in the S6 segment. A similar story applies to caffeine, which
was shown to activate mouse TRPA1 but to inhibit the human
channel (Nagatomo and Kubo, 2008), and menthol, which acti-
vates mammalian TRPA1, blocks nonmammalian TRPA1 (Xiao
et al., 2008), and exerts a bimodal action on murine TRPA1 (Kar-
ashima et al., 2009). Therefore, similar compounds are able to
exert opposite effects in different species and this suggests a
complex gating mechanism for TRPA1 in which amino acid sub-
stitutions at key positions determine agonist binding and gating.676 Neuron 66, 671–680, June 10, 2010 ª2010 Elsevier Inc.The N855S mutation induces a linearization of TRPA1’s current-
voltage relationship, as can be observed with heat-sensitized
TRPV3 channels (Chung et al., 2005). The similarities with sensi-
tized TRPV3 extend to the leftward shift of the voltage depen-
dence and weaker time-dependent current increase at depolariz-
ing potentials. In contrast, while mutant TRPA1 channels have the
same reversal potential as the WT, suggesting no change in ion
permeability, sensitized TRPV3 has an altered reversal potential,
reflecting a change in ion permeability (Chung et al., 2005). This
suggests that different mechanisms underlie the linearization of
voltage dependence in TRPA1 and TRPV3. This view is strength-
ened by the fact that removing external Ca2+ increases TRPV3
current amplitude, whereas it shifts activation curves of both
WT and N855S TRPA1 toward more depolarized potentials while
at the same time decreasing N855S TRPA1 voltage sensitivity.
Figure 5. Activation of hTRPA1-WT and
hTRPA1-N855S with an Endogenous
TRPA1 Ligand and Cold
(A) HEK293 cells expressing hTRPA1-WT (left;
n = 5) or hTRPA1-N855S (right; n = 7) show activa-
tion by 4-HNE and block HC-030031. Currents
were recorded at +100 mV and –100 mV and are
normalized to current at +100 mV. Letters denote
time point at which voltage ramps (shown in B)
were acquired to generate current-voltage rela-
tionships.
(B) Average current-voltage relationship of
hTRPA1-WT and hTRPA1-N855S in the presence
of 100 mM 4-HNE (as shown by letters a and c,
respectively, in A) and after perfusion of 100 mM
4-HNE + 10 mM HC-030031 (as shown by letters
b and d, respectively, in A). Currents are normal-
ized to +100 mV.
(C) Whole-cell current traces of HEK293 cells ex-
pressing hTRPA1-WT (top) or hTRPA1-N855S
(bottom) in response to the indicated voltage
step protocol applied at 25C (left) and 12C
(right). Dotted line shows zero current level.
(D) Mean steady-state activation curves obtained
from tail currents (IT) at 140 mV for hTRPA1-WT
(n = 5) and hTRPA1-N855S (n = 5) in response to
25C and 12C. Error bars in all plots represent
SEM across individual cell measurements.
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be gated by cold. Cold was first proposed not to be a direct acti-
vator of TRPA1 but rather a trigger for an increase in intracellular
[Ca2+] leading to downstream activation of TRPA1 (Zurborg
et al., 2007). This view has been recently challenged with the
demonstration that cold is able to activate TRPA1 in the absence
of Ca2+ both inside and outside the cell (Karashima et al., 2009).
Here we confirm that TRPA1 can be activated by cold and the
mutant channel shows a similar gain of function on cold applica-
tion to that observed with chemical ligands (Table S5). The
evidence of a role for TRPA1 in transducing cold pain is strong,
while a contribution to mechanosensation may be downstreamNeuron 66, 671–of primary mechanotransducers (Kwan
et al., 2006, 2009; Bautista et al., 2006).
The enhanced currents seen with applica-
tion of cold temperatures in the mutant
channel are consistent with a possible
role for TRPA1 as a cold sensor, although
there is no doubt that cold sensors other
than TRPA1 are expressed by sensory
neurons (Munns et al., 2007; Kwan et al.,
2009; Karashima et al., 2009). Finally, the
demonstration that mutant channels are
sensitive to HC-030031 suggests that
specific TRPA1 antagonists may have a
useful therapeutic role in this pain syn-
drome (Eid et al., 2008).
Enhanced channel activity associated
with the N855S mutation is thus consis-
tent with the pain syndrome observed inFEPS patients. Increased activity of the mutant channel when
activated by endogenous mediators provides a plausible mech-
anism that could explain the intense pain experienced by carriers
of the N855S mutation, while the localized effect may reflect high
levels of channel expression or the site of production of acti-
vating ligands. There is evidence that SNP variants in TRPA1
influence differential sensitivity to experimentally induced cold
pain in humans (Kim et al., 2006). Our results provide both
a mechanism and a therapeutic approach to treat the pain
episodes experienced in FEPS, which is the first pain-related
TRP channelopathy to be described in humans. It will be of great
interest to establish whether TRPA1 channel variants or680, June 10, 2010 ª2010 Elsevier Inc. 677
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A Gain-of-Function Mutation in Human TRPA1misregulation contribute to the risk and severity of chronic pain in
patient populations.
EXPERIMENTAL PROCEDURES
Study Subjects
The family studied was identified in Antioquia, in North-West Colombia
(Bedoya et al., 2006). Unaffected controls used for screening of the A2564G
mutation were also ascertained in Antioquia. This study was approved by
the ethics committee of the Universidad de Antioquia and was compliant
with the Declaration of Helsinki 2008. Written informed consent was given
by all study subjects.
Microsatellite Typing and Linkage Analysis
A whole-genome scan using 552 microsatellite markers with an average inter-
marker distance of 8 cM was performed in 13 affected and 10 unaffected
members of the FEPS family (Figure 1). Genotyping was carried out by
deCODE Genetics. Parametric linkage analysis was performed using
LINKAGE (Lathrop et al., 1984, 1986; Lathrop and Lalouel, 1984) (two-point)
and SimWalk2 (Sobel and Lange, 1996) (multipoint). Penetrances were set to
0.985 for both homozygous and heterozygous carriers. The phenocopy rate
was set to 0 and the disease allele frequency to 0.01%. Maximum likelihood
haplotype reconstruction was performed using SimWalk2. For fine-mapping,
an additional 15 microsatellite markers (D8S533, D8S1767, D8S1775,
D8S1792, D8S1117, D8S543, D8S1795, D8S1807, D8S1776, D8S275,
D8S1988, D8S1822, D8S276, D8S85, and D8S1122) were genotyped in all
23 individuals across the initial region of the linkage signal on chromosome
8q12.1–8q24.1 (Figure 1). Genotyping was carried out by PCR using fluores-
cence-labeled primers and standard reaction conditions followed by fragment
length analysis on an ABI3037xl Genetic Analyzer (Applied Biosystems). After
fine mapping, multipoint linkage and haplotype analyses were repeated as
described above.
Candidate Gene Sequencing
After fine mapping, haplotype analysis defined a candidate region delimited by
markers D8S1775 and D8S276 on chromosome 8q13.2–8q22.2. Genes within
this region were identified using the BioMart data mining tool (http://www.
biomart.org) on build 35.1 of the human genome sequence. Among the 287
genes in the region, the following candidate genes were chosen based on their
potential roles in excitability and pain signaling: proenkephalin (PENK), the
cation channel TRPA1, and potassium channel genes KCN B2 and KCN S2.
A further potassium channel gene, KCN V1, though outside the narrow candi-
date region, was located within the initial linkage peak on chromosome 8q23.2
and was therefore included in candidate gene sequencing.
Amplicons covering exons and intron/exon boundaries, as well as the
promoter regions (1 kb upstream of the start of translation), were designed
using Primer3 (http://frodo.wi.mit.edu/; primer sequences are available upon
request), and all amplicons were sequenced bidirectionally in at least one
affected and one unaffected individual using standard dideoxy sequencing
on an ABI 3730xl Genetic Analyzer (Applied Biosystems). Exon 22 of the
TRPA1 gene was sequenced in a similar manner in 13 affected and 9 unaf-
fected members of the Antioquian family (to check for cosegregation of the
A2565G mutation with the phenotype) and in 139 Antioquian population
controls.
Biophysical Studies of TRPA1
A full-length coding sequence of TRPA1 was amplified from IMAGE clone
100015422 (BC148423; Geneservice) using the forward primer (50-CCCCA
AGCTTTCCGGGGTGGGGTCAATGAAGCGCAGCCTGAGGAAGAT) and the
reverse primer (50-CCGCTCGAGCGGATTAGAAGCCTCACTGAAGGTCTGAG
GAGCTAAGGCTCAAGATGGTGTGTTTTTG). This 3426 bp PCR product was
then digested with HINDIII and XhoI and ligated into clone pcDNA3JCPOLRED
to give the final clone TRPA1RED. The final clone (TRPA1RED) was sequenced
entirely and corresponds to TRPA1 RefSeq sequence NM_007332. The clone
TRPA1RED was used as a template to generate the c.A2564G mutation using
the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) according to678 Neuron 66, 671–680, June 10, 2010 ª2010 Elsevier Inc.the manufacturer’s instructions. This clone was sequenced entirely by stan-
dard methods.
HEK293 cells were transfected with cDNA clones using Lipofectamine 2000.
Intracellular free calcium was measured using dual excitation of the calcium-
sensitive fluorescence probe Fura-2 (Molecular Probes). Patch clamp electro-
physiological recordings were performed using an Axopatch 200B patch-
clamp amplifier (Molecular Devices). Full details of transfection, calcium
imaging, and recording protocols are to be found in Supplemental Information.
Quantitative Sensory Testing
QST was performed on nine patients with FEPS as well as in eight unaffected
siblings who did not carry the mutation and who were matched as far as
possible for age and sex. None of the subjects had comorbid medical condi-
tions (such as diabetes), which could impair sensory function, were taking
medication, or were experiencing ongoing pain at the time QST was per-
formed. The experimenter was blind to the subjects’ genotype. Vibration
detection threshold was measured using a 128 Hz Rydel-Seiffer tuning fork
placed on the distal phalanx of the index finger. Three readings were taken
and the mean was calculated. The mechanical detection threshold was deter-
mined using von Frey hairs (0.06 to 644 mN). Five threshold determinations
were determined using the ‘‘method of limits’’ with ascending and descending
stimulus intensities and the final threshold was the geometric mean of these
five series. Pressure pain threshold was determined over the ulnar eminence
using a pressure gauge (FDN100; Wagner instruments USA; probe area of
1 cm2 up to 1000 kPa). Thermal thresholds were determined on the volar fore-
arm using a 16 316 mm probe held at an adaption temperature of 32C con-
nected to a servo-controlled Peltier device (TSA-II; Medoc). Thresholds were
obtained with a ramp stimulus (1C/S) that terminated when the subject
pressed a button at which point probe temperature rapidly returned to the
adaption temperature of 32C. The mean of three readings was taken. Cold
pressor pain threshold was determined by measuring the latency to the first
pain sensation after immersion of the hand up to the level of the wrist in ice
water kept at 4C. This was repeated three times with at least 2 min between
each test (Martikainen et al., 2004).
Mustard Oil-Evoked Sensitization
200 ml of 50% mustard oil (Allyl isothiocyanate; Fluka; v/v in olive oil) was
applied to a 0.64 cm2 region of the volar forearm for 10 min. During this period
pain scores were recorded using electronic VAS. An acetate template was
used to mark dots at 1 cm increments along eight spokes radiating out from
the area of mustard oil application. 10, 30, and 60 min after mustard oil appli-
cation, sensory testing was performed starting at the outermost spoke to act
as reference and moving toward the area of mustard oil application. Punctate
hyperalgesia was determined using a 100 mN filament (Bailey Instruments)
applied once and brush evoked allodynia using a No. 2 sable paintbrush (Just-
brushes) applying four strokes of 1 cm perpendicularly to the spoke at each
point. The area of flare, punctate hyperalgesia, and brush-evoked allodynia
was determined as per Norbury et al. (2007). The primary area of mustard oil
application was subtracted from these figures to determine the area of
secondary change for brush-evoked allodynia and punctate hyperalgesia.
Determination of Intraepidermal Nerve Fiber Density
3 mm punch skin biopsies were taken from the upper arm, a commonly
affected region during pain. Skin was immersion fixed in 4% paraformalde-
hyde overnight and then transferred to 20% sucrose in 0.1 M phosphate buffer
for 24 hr. 50 mm free floating sections were cut and immunostained using an
antibody directed against the pan-neuronal marker PGP 9.5 (1:1000 ultra-
clone), and intraepidermal nerve fiber density was calculated as per Lauria
et al. (2005).SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, five tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.neuron.2010.04.030.
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